郭美君;李昊;杜珊珊;杨晓艺;谢春;李建东;

• 1:中国疾病预防控制中心病毒病预防控制所卫生部医学病毒和病毒病重点实验室
• 2:贵州医科大学公共卫生与健康学院职业卫生与环境卫生学系贵州医科大学环境污染与疾病监控教育部重点实验室

摘要(Abstract)：

白细胞介素6(Interleukin 6,IL-6)是一种多效性细胞因子，对机体免疫系统和非免疫系统的细胞均有较大影响，可发挥促炎或抗炎作用，影响机体生理平衡。病毒感染致病往往包括直接损伤和免疫病理机制，免疫调节是影响疾病进程和临床结果的重要干预靶点。IL-6拮抗剂的临床应用经验提示，靶向该细胞因子可改善疾病结局，但如何以及何时阻断是仍需进一步研究的重要领域。为增加对IL-6在疾病进程中的作用机制的理解，我们对IL-6主要功能、信号转导途径以及在病毒感染与免疫中的作用进行了初步的综述分析。

关键词(KeyWords)： 白细胞介素6(IL-6);白细胞介素受体(IL-6R);病毒感染;免疫

Abstract:

Keywords:

基金项目(Foundation): 重大传染病防治专项（项目号：2016ZX10004222-002）,题目：白细胞介素6和病毒感染与免疫~~

作者(Authors): 郭美君;李昊;杜珊珊;杨晓艺;谢春;李建东;

DOI: 10.13242/j.cnki.bingduxuebao.004248

参考文献(References)：

• [1] Rouse B T, Sehrawat S. Immunity and immunopathology to viruses:what decides the outcome?[J/OL]. Nat Rev Immunol,2010,10(7):514-526.DOI:10.1038/nri2802.
• [2] Schett G, Elewaut D, Mcinnes I B, Dayer J M, Neurath M F. How cytokine networks fuel inflammation:Toward a cytokine-based disease taxonomy[J/OL]. Nat Med,2013,19(7):822-824.DOI:10.1038/nm.3260.
• [3] van Eijk L E, Binkhorst M, Bourgonje A R, Offringa A K, Mulder D J, Bos E M, Kolundzic N, Abdulle A E,van der Voort P H, Olde R M, van der Hoeven J G,den Dunnen W F, Hillebrands J L, van Goor H.COVID-19:immunopathology, pathophysiological mechanisms, and treatment options[J/OL]. J Pathol,2021,254(4):307-331.DOI:10.1002/path.5642.
• [4] Zizzo G, Tamburello A, Castelnovo L, Laria A,Mumoli N, Faggioli P M, Stefani I, Mazzone A.Immunotherapy of COVID-19:Inside and Beyond IL-6Signalling[J/OL]. Front Immunol,2022,13:795315.DOI:10.3389/fimmu.2022.795315.
• [5] Jones S A, Scheller J, Rose-John S. Therapeutic strategies for the clinical blockade of IL-6/gp130signaling[J/OL]. J Clin Invest,2011,121(9):3375-3383.DOI:10.1172/JCI57158.
• [6] Bethin K E, Vogt S K, Muglia L J. Interleukin-6 is an essential, corticotropin-releasing hormone-independent stimulator of the adrenal axis during immune system activation[J/OL]. Proc Natl Acad Sci U S A,2000,97(16):9317-9322.DOI:10.1073/pnas.97.16.9317.
• [7] Bethin K E, Vogt S K, Muglia L J. Interleukin-6 is an essential, corticotropin-releasing hormone-independent stimulator of the adrenal axis during immune system activation[J/OL]. Proc Natl Acad Sci U S A,2000,97(16):9317-9322.DOI:10.1073/pnas.97.16.9317.
• [8] Masuda K, Ripley B, Nishimura R, Mino T, Takeuchi O, Shioi G, Kiyonari H, Kishimoto T. Arid5a controls IL-6 mRNA stability, which contributes to elevation of IL-6 level in vivo[J/OL]. Proc Natl Acad Sci U S A,2013, 110(23):9409-9414. DOI:10.1073/pnas.1307419110.
• [9] Waage A, Brandtzaeg P, Halstensen A, Kierulf P,Espevik T. The complex pattern of cytokines in serum from patients with meningococcal septic shock.Association between interleukin 6, interleukin 1, and fatal outcome[J/OL]. J Exp Med,1989,169(1):333-338.DOI:10.1084/jem.169.1.333.
• [10] Mroczko B, Groblewska M, Gryko M, Kedra B,Szmitkowski M. Diagnostic usefulness of serum interleukin 6(IL-6)and C-reactive protein(CRP)in the differentiation between pancreatic cancer and chronic pancreatitis[J/OL]. J Clin Lab Anal,2010,24(4):256-261.DOI:10.1002/jcla.20395.
• [11] Dienz O, Rud J G, Eaton S M, Lanthier P A, Burg E,Drew A, Bunn J, Suratt B T, Haynes L, Rincon M.Essential role of IL-6 in protection against H1N1influenza virus by promoting neutrophil survival in the lung[J/OL]. Mucosal Immunol,2012,5(3):258-266.DOI:10.1038/mi.2012.2.
• [12] Hoge J, Yan I, Janner N, Schumacher V, Chalaris A,Steinmetz O M, Engel D R, Scheller J, Rose-John S,Mittrucker H W. IL-6 controls the innate immune response against Listeria monocytogenes via classical IL-6 signaling[J/OL]. J Immunol,2013,190(2):703-711.DOI:10.4049/jimmunol.1201044.
• [13] Neveu W A, Allard J B, Dienz O, Wargo M J,Ciliberto G, Whittaker L A, Rincon M. IL-6 is required for airway mucus production induced by inhaled fungal allergens[J/OL]. J Immunol,2009,183(3):1732-1738.DOI:10.4049/jimmunol.0802923.
• [14] Liu F, Poursine-Laurent J, Wu H Y, Link D C.Interleukin-6 and the granulocyte colony-stimulating factor receptor are major independent regulators of granulopoiesis in vivo but are not required for lineage commitment or terminal differentiation[J]. Blood,1997,90(7):2583-2590.
• [15] Lauder S N, Jones E, Smart K, Bloom A, Williams A S, Hindley J P, Ondondo B, Taylor P R, Clement M,Fielding C, Godkin A J, Jones S A, Gallimore A M.Interleukin-6 limits influenza-induced inflammation and protects against fatal lung pathology[J/OL]. Euro J Immunol,2013,43(10):2613-2625. DOI:10.1002/eji.201243018.
• [16] Jenkins B J, Grail D, Inglese M, Quilici C, Bozinovski S, Wong P, Ernst M. Imbalanced gp130-dependent signaling in macrophages alters macrophage colonystimulating factor responsiveness via regulation of c-fms expression[J/OL]. Mol Cell Biol,2004,24(4):1453-1463.DOI:10.1128/MCB.24.4.1453-1463.2004.
• [17] Hegde S, Pahne J, Smola-Hess S. Novel immunosuppressive properties of interleukin-6 in dendritic cells:inhibition of NF-kappaB binding activity and CCR7 expression[J/OL]. FASEB J,2004,18(12):1439-1441.DOI:10.1096/fj.03-0969fje.
• [18] Rosser E C, Oleinika K, Tonon S, Doyle R, Bosma A, Carter N A, Harris K A, Jones S A, Klein N,Mauri C. Regulatory B cells are induced by gut microbiota-driven interleukin-1beta and interleukin-6production[J/OL]. Nat Med,2014,20(11):1334-1339.DOI:10.1038/nm.3680.
• [19] Barr T A, Brown S, Mastroeni P, Gray D. TLR and B Cell Receptor Signals to B Cells Differentially Program Primary and Memory Th1 Responses toSalmonella enterica[J/OL]. The Journal of Immunology,2010,185(5):2783-2789.DOI:10.4049/jimmunol.1001431.
• [20] Ma C S, Deenick E K, Batten M, Tangye S G. The origins, function, and regulation of T follicular helper cells[J/OL]. J Exp Med,2012,209(7):1241-1253.DOI:10.1084/jem.20120994.
• [21] Harker J A, Lewis G M, Mack L, Zuniga E I. Late interleukin-6 escalates T follicular helper cell responses and controls a chronic viral infection[J/OL]. Science,2011, 334(6057):825-829. DOI:10.1126/science.1208421.
• [22] Hoogenraad C C, Riol-Blanco L. Interleukin-17:A Social Cytokine[J/OL]. Cell,2020,181(3):517-519.DOI:10.1016/j.cell.2020.03.060.
• [23] Kopf M, Baumann H, Freer G, Freudenberg M,Lamers M, Kishimoto T, Zinkernagel R, Bluethmann H, Kohler G. Impaired immune and acute-phase responses in interleukin-6-deficient mice[J/OL].Nature,1994,368(6469):339-342. DOI:10.1038/368339a0.
• [24] Mauer J, Chaurasia B, Goldau J, Vogt M C, Ruud J,Nguyen K D, Theurich S, Hausen A C, Schmitz J,Bronneke H S, Estevez E, Allen T L, Mesaros A,Partridge L, Febbraio M A, Chawla A, Wunderlich F T, Bruning J C. Signaling by IL-6 promotes alternative activation of macrophages to limit endotoxemia and obesity-associated resistance to insulin[J/OL]. Nat Immunol,2014,15(5):423-430.DOI:10.1038/ni.2865.
• [25] Jones S A, Scheller J, Rose-John S. Therapeutic strategies for the clinical blockade of IL-6/gp130signaling[J/OL]. J Clin Invest,2011,121(9):3375-3383.DOI:10.1172/JCI57158.
• [26] Skiniotis G, Boulanger M J, Garcia K C, Walz T.Signaling conformations of the tall cytokine receptor gp130 when in complex with IL-6 and IL-6 receptor[J/OL]. Nat Struct Mol Biol,2005,12(6):545-551.DOI:10.1038/nsmb941.
• [27] Heinrich P C, Behrmann I, Haan S, Hermanns H M,Muller-Newen G, Schaper F. Principles of interleukin(IL)-6-type cytokine signalling and its regulation[J/OL]. Biochem J,2003,374(Pt 1):1-20.DOI:10.1042/BJ20030407.
• [28] Campbell I L, Erta M, Lim S L, Frausto R, May U,Rose-John S, Scheller J, Hidalgo J. Trans-signaling is a dominant mechanism for the pathogenic actions of interleukin-6 in the brain[J/OL]. J Neurosci,2014,34(7):2503-2513. DOI:10.1523/JNEUROSCI. 2830-13.2014.
• [29] Mcloughlin R M, Hurst S M, Nowell M A, Harris D A, Horiuchi S, Morgan L W, Wilkinson T S,Yamamoto N, Topley N, Jones S A. Differential regulation of neutrophil-activating chemokines by IL-6and its soluble receptor isoforms[J/OL]. J Immunol,2004, 172(9):5676-5683. DOI:10.4049/jimmunol.172.9.5676.
• [30] Jones S A, Horiuchi S, Topley N, Yamamoto N,Fuller G M. The soluble interleukin 6 receptor:mechanisms of production and implications in disease[J/OL]. FASEB J,2001,15(1):43-58.DOI:10.1096/fj.99-1003rev.
• [31] Garbers C, Monhasery N, Aparicio-Siegmund S,Lokau J, Baran P, Nowell M A, Jones S A, Rose-John S, Scheller J. The interleukin-6 receptor Asp358Ala single nucleotide polymorphism rs2228145 confers increased proteolytic conversion rates by ADAM proteases[J/OL]. Biochim Biophys Acta,2014,1842(9):1485-1494.DOI:10.1016/j.bbadis.2014.05.018.
• [32] Velazquez-Salinas L, Verdugo-Rodriguez A, Rodriguez L L, Borca M V. The Role of Interleukin 6 During Viral Infections[J/OL]. Front Microbiol,2019,10:1057.DOI:10.3389/fmicb.2019.01057.
• [33] Coomes E A, Haghbayan H. Interleukin-6 in Covid-19:A systematic review and meta-analysis[J/OL]. Rev Med Virol,2020,30(6):1-9.DOI:10.1002/rmv.2141.
• [34] Liu M, Lei X, Yu H, Zhang J, Yu X. Correlation of cytokine level with the severity of severe fever with thrombocytopenia syndrome[J/OL]. Virol J,2017,14(1).DOI:10.1186/s12985-016-0677-1.
• [35] Liu Q, He B, Huang S Y, Wei F, Zhu X Q. Severe fever with thrombocytopenia syndrome, an emerging tick-borne zoonosis[J/OL]. Lancet Infect Dis,2014,14(8):763-772.DOI:10.1016/S1473-3099(14)70718-2.
• [36] Sun Y, Jin C, Zhan F, Wang X, Liang M, Zhang Q,Ding S, Guan X, Huo X, Li C, Qu J, Wang Q, Zhang S, Zhang Y, Wang S, Xu A, Bi Z, Li D. Host cytokine storm is associated with disease severity of severe fever with thrombocytopenia syndrome[J/OL]. J Infect Dis,2012,206(7):1085-1094. DOI:10.1093/infdis/jis452.
• [37] Kyriakidis I, Papa A. Serum TNF-alpha, sTNFR1, IL-6, IL-8 and IL-10 levels in hemorrhagic fever with renal syndrome[J/OL]. Virus Res,2013,175(1):91-94.DOI:10.1016/j.virusres.2013.03.020.
• [38]江丽芳江振友郭辉玉.登革病毒对人血管内皮细胞产生细胞因子的影响[J].中华微生物学和免疫学杂志，1998(04):58-61
• [39]史毓杰江振友.登革病毒促进人树突状细胞分泌TNF-α、IL-6、IFN-γ的动态观察[J].中国病理生理杂志，2005(06):1203-1206
• [40] Alagarasu K, Kaushal H, Shinde P, Kakade M,Chaudhary U, Padbidri V, Sangle S A, Salvi S,Bavdekar A R, D'Costa P, Choudhary M L. TNFA and IL10 Polymorphisms and IL-6 and IL-10 Levels Influence Disease Severity in Influenza A(H1N1)pdm09Virus Infected Patients[J/OL]. Genes(Basel),2021,12(12).DOI:10.3390/genes12121914.
• [41] Koshiol J, Argirion I, Liu Z, Kim L T, O'Brien T R,Yu K, Mcglynn K A, Petrick J L, Pinto L, Chen C J,Hildesheim A, Pfeiffer R M, Lee M H, Yang H I.Immunologic markers and risk of hepatocellular carcinoma in hepatitis B virus-and hepatitis C virusinfected individuals[J/OL]. Aliment Pharmacol Ther,2021,54(6):833-842.DOI:10.1111/apt.16524.
• [42] Trovato M, Ruggeri R M, Sciacchitano S, Vicchio T M, Picerno I, PellicanòG, Valenti A, Visalli G. Serum interleukin-6 levels are increased in HIV-infected patients that develop autoimmune disease during longterm follow-up[J/OL]. Immunobiology,2018,223(3):264-268.DOI:10.1016/j.imbio.2017.10.039.
• [43] Kaya S, Elaldi N, Kubar A, Gursoy N, Yilmaz M,Karakus G, Gunes T, Polat Z, Gozel M G, Engin A,Dokmetas I, Bakir M, Yilmaz N, Sencan M. Sequential determination of serum viral titers, virus-specific IgG antibodies, and TNF-α, IL-6, IL-10, and IFN-γ levels in patients with Crimean-Congo hemorrhagic fever[J/OL]. BMC Infectious Diseases,2014,14(1):416.DOI:10.1186/1471-2334-14-416.
• [44] Tanabe I, Santos E C, Tanabe E, Souza S, Santos F,Taniele-Silva J, Ferro J, Lima M C, Moura A A,Anderson L, BassiêJ. Cytokines and chemokines triggered by Chikungunya virus infection in human patients during the very early acute phase[J/OL]. Trans R Soc Trop Med Hyg,2019,113(11):730-733. DOI:10.1093/trstmh/trz065.
• [45] Harker J A, Lewis G M, Mack L, Zuniga E I. Late Interleukin-6 Escalates T Follicular Helper Cell Responses and Controls a Chronic Viral Infection[J/OL]. Science,2011,334(6057):825-829.DOI:10.1126/science.1208421.
• [46] Luo J, Zhang B, Wu Y, Tian Q, Mo M, Long T, Mei M, Fan R, Lyu Z, Jiang H, Wu F, Lin Y, Guo X.Recombinant rabies virus expressing interleukin-6enhances the immune response in mouse brain[J/OL].Arch Virol,2018,163(7):1889-1895. DOI:10.1007/s00705-018-3808-8.
• [47] Tanaka T, Narazaki M, Kishimoto T. IL-6 in inflammation, immunity, and disease[J/OL]. Cold Spring Harb Perspect Biol,2014,6(10):a16295. DOI:10.1101/cshperspect.a016295.
• [48] Fernandez-Sainz I, Gladue D P, Holinka L G,O'Donnell V, Gudmundsdottir I, Prarat M V, Patch J R, Golde W T, Lu Z, Zhu J, Carrillo C, Risatti G R,Borca M V. Mutations in classical swine fever virus NS4B affect virulence in swine[J/OL]. J Virol,2010,84(3):1536-1549.DOI:10.1128/JVI.02050-09.
• [49] Palumbo G A, Scisciani C, Pediconi N, Lupacchini L,Alfalate D, Guerrieri F, Calvo L, Salerno D, Di Cocco S, Levrero M, Belloni L. IL6 Inhibits HBV Transcription by Targeting the Epigenetic Control of the Nuclear cccDNA Minichromosome[J/OL]. PLoS One,2015, 10(11):e142599. DOI:10.1371/journal.pone.0142599.
• [50] Fielding C A, Mcloughlin R M, Colmont C S,Kovaleva M, Harris D A, Rose-John S, Topley N,Jones S A. Viral IL-6 blocks neutrophil infiltration during acute inflammation[J/OL]. J Immunol,2005,175(6):4024-4029.DOI:10.4049/jimmunol.175.6.4024.
• [51] Moore P S, Boshoff C, Weiss R A, Chang Y.Molecular mimicry of human cytokine and cytokine response pathway genes by KSHV[J/OL]. Science,1996, 274(5293):1739-1744. DOI:10.1126/science.274.5293.1739.
• [52] Chatterjee M, Osborne J, Bestetti G, Chang Y, Moore P S. Viral IL-6-induced cell proliferation and immune evasion of interferon activity[J/OL]. Science,2002,298(5597):1432-1435.DOI:10.1126/science.1074883.
• [53] Chang Y, Cesarman E, Pessin M S, Lee F, Culpepper J, Knowles D M, Moore P S. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma[J/OL]. Science,1994,266(5192):1865-1869.DOI:10.1126/science.7997879.
• [54] Wu W, Dietze K K, Gibbert K, Lang K S, Trilling M,Yan H, Wu J, Yang D, Lu M, Roggendorf M,Dittmer U, Liu J. TLR ligand induced IL-6 counterregulates the anti-viral CD8(+)T cell response during an acute retrovirus infection[J/OL]. Sci Rep,2015,5:10501.DOI:10.1038/srep10501.
• [55] Bardhan K, Anagnostou T, Boussiotis V A. The PD1:PD-L1/2 Pathway from Discovery to Clinical Implementation[J/OL]. Front Immunol,2016,7:550.DOI:10.3389/fimmu.2016.00550.
• [56] Murdaca G, Paladin F, Tonacci A, Isola S, Allegra A,Gangemi S. The Potential Role of Cytokine Storm Pathway in the Clinical Course of Viral Respiratory Pandemic[J/OL]. Biomedicines,2021,9(11). DOI:10.3390/biomedicines9111688.
• [57] Bryden S R, Dunlop J I, Clarke A T, Fares M, Pingen M, Wu Y, Willett B J, Patel A H, Gao G F, Kohl A,Brennan B. Exploration of immunological responses underpinning severe fever with thrombocytopenia syndrome virus infection reveals IL-6 as a therapeutic target in an immunocompromised mouse model[J/OL].PNAS Nexus,2022,1(1):c24. DOI:10.1093/pnasnexus/pgac024.